NeuroSense Provides Update on Nasdaq Listing Compliance
Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value requirement CAMBRIDGE, Mass., Oct. 2, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd....
Covered in this story
What has happened since
- NeuroSense Therapeutics is up 2.4% since this was published, 3 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $NRSN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NeuroSense Therapeutics →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.